A Pilot Screen of a Novel Peptide Hormone Library Identified Candidate GPR83 Ligands.


Journal

SLAS discovery : advancing life sciences R & D
ISSN: 2472-5560
Titre abrégé: SLAS Discov
Pays: United States
ID NLM: 101697563

Informations de publication

Date de publication:
Oct 2020
Historique:
pubmed: 28 7 2020
medline: 17 7 2021
entrez: 28 7 2020
Statut: ppublish

Résumé

The identification of novel peptide hormones by functional screening is challenging because posttranslational processing is frequently required to generate biologically active hormones from inactive precursors. We developed an approach for functional screening of novel potential hormones by expressing them in endocrine host cells competent for posttranslational processing. Candidate preprohormones were selected by bioinformatics analysis, and stable endocrine host cell lines were engineered to express the preprohormones. The production of mature hormones was demonstrated by including the preprohormones insulin and glucagon, which require the regulated secretory pathway for production of the active forms. As proof of concept, we screened a set of G-protein-coupled receptors (GPCRs) and identified protein FAM237A as a specific activator of GPR83, a GPCR implicated in central nervous system and regulatory T-cell function. We identified the active form of FAM237A as a C-terminally cleaved, amidated 9 kDa secreted protein. The related protein FAM237B, which is 64% homologous to FAM237A, demonstrated similar posttranslational modification and activation of GPR83, albeit with reduced potency. These results demonstrate that our approach is capable of identifying and characterizing novel hormones that require processing for activity.

Identifiants

pubmed: 32713278
doi: 10.1177/2472555220934807
pii: S2472-5552(22)06637-0
doi:

Substances chimiques

GPR83 protein, human 0
Ligands 0
Peptide Hormones 0
Peptide Library 0
Receptors, G-Protein-Coupled 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1047-1063

Auteurs

Nathan A Sallee (NA)

Five Prime Therapeutics Inc., South San Francisco, CA, USA.
Maze Therapeutics Inc., South San Francisco, CA, USA.

Ernestine Lee (E)

Five Prime Therapeutics Inc., South San Francisco, CA, USA.

Atossa Leffert (A)

Five Prime Therapeutics Inc., South San Francisco, CA, USA.

Silvia Ramirez (S)

Five Prime Therapeutics Inc., South San Francisco, CA, USA.
BioMarin Pharmaceutical Inc., San Rafael, CA, USA.

Arthur D Brace (AD)

Five Prime Therapeutics Inc., South San Francisco, CA, USA.

Robert Halenbeck (R)

Five Prime Therapeutics Inc., South San Francisco, CA, USA.
BioMarin Pharmaceutical Inc., San Rafael, CA, USA.

W Michael Kavanaugh (WM)

Five Prime Therapeutics Inc., South San Francisco, CA, USA.
CytomX Therapeutics Inc., South San Francisco, CA, USA.

Kathleen M C Sullivan (KMC)

Five Prime Therapeutics Inc., South San Francisco, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH